15 results about "Plasma serum" patented technology

The invention discloses a plasma or serum exosome separation method which comprises the following steps: firstly, coupling an antibody for resisting four transmembrane protein CD81 on the surface of an exosome by using a magnetic bead to form an immunomagnetic bead; pretreating a serum / plasma sample, enriching exosomes, co-incubating with the immunomagnetic beads, washing the magnetic beads after incubation capture is completed, and washing off uncombined impurities; after being captured, the exosome can be directly cracked, the magnetic beads are removed for downstream experiments, or the magnetic beads are eluted to obtain the complete exosome. The exosome affinity antibody is matched with the magnetic beads, the plasma / serum sample exosome is separated, the unique affinity separation technology not only can remove high-abundance protein in the serum / plasma sample, but also can eliminate other vesicles with similar membrane structures with the exosome, so that the purity of the separated exosome is far higher than that of the exosome obtained by other separation methods.

Soluble gp120 (sgp120) is associated to HIV-1-induced immune dysfunction, such as chronic immune activation. However, the detection of sgp120 in biological fluids such as plasma, serum, cervicovaginal fluids, and cerebrospinal fluids is challenging. The present application relates to novel methods and kits for the detection of sgp120 in biological fluids. These methods and kits are based on the use of specific combinations of sgp120-binding molecules recognizing particular domains of sgp120, notably the N-terminal 8-stranded β-sandwich structure, the constant region 1 and 2 (C1-C2) portion, the bridging sheet of the Co-Receptor Binding Site (CoRBS), and / or the CD4-binding domain.

The application provides a full-passive microfluidic whole blood sample preparation device, which comprises, from bottom to top, a bottom support layer, a bottom hydrophilic layer, a bottom adhesive layer, a middle main body layer, a liquid outlet channel layer, an upper surface hydrophilic layer of the liquid outlet channel, a first intermediate adhesive layer, an upper layer main body layer, a second intermediate adhesive layer, a top cover layer and a product collection and storage cavity sealing patch which are laminated and assembled in sequence. The application does not need any external driving force or active surface treatment, and only relies on the material properties and ingenious structure design, so that the plasma / serum can be automatically and efficiently separated from trace whole blood, and the application has the advantages of simple structure, low cost, convenient operation, one-time use, instant detection application and the like.

The invention relates to a method for detecting multiple neurotransmitter compounds based on high performance liquid chromatography-tandem mass spectrometry. The method comprises the following steps: S1, preparing a standard curve solution of each neurotransmitter and drawing a standard curve; s2, precipitating protein in the plasma / serum sample by using a protein precipitant, and taking supernate; s3, adding a derivatization reagent into the supernate for derivatization reaction to obtain a to-be-detected solution; s4, simultaneously loading the to-be-detected solution and the standard curve solution to high performance liquid chromatography-tandem mass spectrometry for joint detection to obtain the peak area value of each neurotransmitter compound in the to-be-detected solution; s5, calculating the concentration of each neurotransmitter compound in the liquid to be detected according to the standard curve of each neurotransmitter compound in combination with the peak area value obtained in the step S3; wherein the neurotransmitter compound comprises a derivatization product of a neurotransmitter containing a primary amine group and / or a phenolic hydroxyl group and a neurotransmitter containing a secondary amine group, and the derivatization reagent is a benzoyl chloride-acetonitrile solution.

The present invention relates to a cell-free transcriptional electrochemical biosensor and to the use of the same for detecting specific molecular analytes, such as specific antibodies, proteins, small molecules, nucleic acids, and derivatives thereof, in complex arrays of biological samples, such as plasma, serum, blood, saliva, sweat, and the like, wherein said biosensor is based on the activation of the transcription of a specific RNA strand, induced by recognition with the analyte. The invention further relates to a method for the detection of specific molecular analytes in complex arrays of biological samples, said method being based on the use of said cell-free transcriptional electrochemical biosensor.

The invention discloses airflow spinning silicon dioxide fiber sponge for portable plasma / serum separation, and belongs to the technical field of biomedical materials. The problems that a traditional centrifugal machine is poor in portability, and a commercial filter element is high in hemolysis rate and low in filtering efficiency due to the fact that fibers are short and tips are exposed are solved. According to the technical scheme, the method comprises the following steps: (1) preparing long and bent micron-sized silicon dioxide fibers by adopting an airflow spinning technology, forming a three-dimensional interwoven network structure, and reducing the damage of fiber tips to red blood cells; (2) mixing tetraethoxysilane serving as a silicon source with polyvinyl alcohol (PVA) and polyethylene oxide (PEO) to prepare a precursor solution, spinning, densifying and drying, and calcining at 800 DEG C to generate beta-type silicon dioxide sponge; and (3) the porosity and the mechanical strength are optimized, so that the erythrocyte interception rate is more than 99%, the serum permeation speed reaches 0.8 mL / min, and the hemolysis rate is less than 0.5%. The method is suitable for instant diagnosis (POCT) scenes such as first aid and field rescue, plasma / serum can be efficiently separated without a centrifugal machine, and the method has the advantages of being low in hemolysis, high in flux, high in biocompatibility and the like.

The application belongs to the technical field of biology, and particularly relates to a novel biomarker for screening and diagnosis of beta-thalassemia and application thereof. The application provides a novel polypeptide cluster biomarker for screening and diagnosis of beta-thalassemia based on polypeptides in plasma / serum obtained in vitro from patients, which has the advantages of high sensitivity and high specificity. The biomarker provided by the application can be detected by mass spectrometry, and the detection method is stable and efficient, and does not need to adopt cumbersome steps for inspection, thereby providing laboratory support for screening and diagnosis and treatment of beta-thalassemia.

The invention discloses a method for efficiently and rapidly extracting nucleic acid based on a paramagnetic particle method, and belongs to the technical field of molecular biological detection. A lysis solution used in the method is prepared from the following components: 1 to 4 M of guanidine isothiocyanate, 0.5 to 1.5 percent of Triton X-100, 0.2 to 1 percent of Tween 20, 10 to 50 mM of EDTA (Ethylene Diamine Tetraacetic Acid), 10 to 50 mM of DTT (Diethylene Terephthalate), 4 to 8 percent of PEG (Polyethylene Glycol) 8000 and 1 to 3 M of NaCl. According to the method, ethanol with gradient concentration is used for washing. According to the method disclosed by the invention, the optimized lysis solution is combined with gradient concentration ethanol for washing, so that rapid lysis of cells and efficient extraction of nucleic acid can be realized within 10 minutes; according to the method, volatile organic reagents such as chloroform and Trizol do not need to be used, so that the personal safety of operators is guaranteed; the method is simple in process operation, low in professional requirement on experimental operators and suitable for various complex samples such as plasma and serum, the technical application range is expanded due to wide compatibility, and diversified research requirements are met.

The invention belongs to the technical field of biology, and particularly relates to a novel biomarker for screening and diagnosing beta-thalassemia and application of the novel biomarker. The invention provides a novel polypeptide cluster biomarker for screening and diagnosing beta-thalassemia based on polypeptide in plasma / serum obtained in vitro from a patient, and the novel polypeptide cluster biomarker has the advantages of high sensitivity and high specificity. According to the biomarker provided by the invention, detection can be carried out through a mass spectrometry technology, the detection method is stable and efficient, tedious steps for detection are not needed, and laboratory support is provided for screening, diagnosis and treatment of beta-thalassemia.

The present invention relates to methods of detecting, characterizing, measuring, and quantifying human and humanized antibodies, and conjugates thereof, that may be present in pre-clinical animal biological samples, or human biological samples, including plasma / serum and tissue samples.

Methods are disclosed to detect, characterize, measure, and quantify human and humanized antibodies, and their conjugates, that may be present in pre-clinical animal biological samples, or human biological samples, including plasma / serum and tissue samples.

The invention discloses a binding solution, a kit and a method for extracting miRNA in a plasma / serum sample based on a paramagnetic particle method, and belongs to the technical field of molecular biology. The binding solution comprises alcohols and formamide and / or a derivative thereof, and is prepared by using an acidic buffer solution. When the binding solution, the kit or the method provided by the invention is used for extracting the free miRNA in the plasma / serum sample, the miRNA recovery rate can be greatly improved, the problem that the miRNA recovery rate is low when complex samples such as plasma are extracted by a traditional paramagnetic particle method is solved, and a more sufficient sample is provided for subsequent accurate detection. The binding solution and the kit are simple in component and easy to prepare, the method is easy to operate, no additional step is introduced, application and popularization are very easy, and the binding solution and the kit have wide application prospects in the fields of research, clinical diagnosis and the like related to plasma free miRNA.

The invention provides application of SV2A protein as a quality control internal standard substance for a protein extraction process based on a nanometer material and a quality control method. The application comprises the following steps: before protein extraction, adding SV2A protein into the nano material, adding the heavy-labeled peptide fragment after enzymolysis, quantifying signals of the light-labeled peptide fragment and the heavy-labeled peptide fragment through mass spectrometry, calculating the recovery rate, and judging whether the process is qualified or not according to the recovery rate result. The light-labeled peptide fragment is a characteristic enzymolysis product of SV2A protein, and the heavy-labeled peptide fragment is an isotope-labeled synthetic peptide fragment corresponding to the light-labeled peptide fragment. According to the method, the competitive adsorption deviation in the extraction process of complex samples (plasma, serum, urine, cerebrospinal fluid, tissue and the like) can be monitored in real time, magnetic or non-magnetic polystyrene, a molecular sieve, silicon dioxide, graphene oxide and other multiple types of nano materials are matched, and the reliability of proteomics data is remarkably improved.

The application discloses a diagnosis marker for early chronic obstructive pulmonary disease (COPD) and application thereof, and relates to the technical field of biomedicine. The application is based on the fact that the immunoglobulin glycosylation modification index in plasma / serum can be used as a marker when being combined with the lung function detection index FEV1 / FVC, so as to distinguish the high-risk population of early COPD from the healthy population. The method has the advantages of high prediction accuracy, low cost, high throughput and easy operation.

The invention provides a jet-spun yttrium-stabilized zirconia (YSZ) nanofiber sponge for portable plasma / serum separation, which has efficient plasma / serum separation performance, low hemolysis rate, high mechanical strength and good filtering efficiency, and is suitable for portable blood detection equipment. Zirconium n-propoxide and yttrium nitrate hexahydrate are used as precursors and are mixed with acetylacetone in ethyl alcohol, PVP is added, and stirring is performed to form a viscous solution. And micron fibers are spun through an airflow spinning device and are stacked into a porous sponge structure. And drying, pressurizing and densifying, and calcining at high temperature to remove organic components, thereby obtaining the pure white YSZ fiber sponge. The material overcomes the inconvenience of a traditional centrifugal method, has large-scale application potential, is uniform in fiber structure and high in porosity, and improves the blood separation efficiency and the material stability.